Dr. Moncef Slaoui is the Chairman of Vaccines at GlaxoSmithKline PLC (GSK) and has been responsible for the global vaccines business at GSK through its integration of the Novartis vaccine acquisition in 2015. At GSK, Dr. Slaoui has been responsible for the franchise commercial organization, focused on new product launches and lifecycle management. He oversees GSK’s venture capital arm, SR One, and other venture capital partnerships, as well as its groundbreaking Bioelectronics R&D strategy. He is also a member of the Corporate Executive Team and Board of Directors.
Prior to his current role, Dr. Slaoui served as Chairman, GSK R&D for eight years. In this position, he spearheaded a profound overhaul of GSK’s pharmaceutical R&D, resulting in a substantial improvement in productivity, with a late-stage pipeline comprising more than 30 Phase III programs and a totally redesigned discovery organization comprising 38 highly focused and accountable Discovery Performance Units. In his role as leader of the Franchise Commercial Operation, he spearheaded a deep transformation of GSK’s launch and commercial strategy capabilities, and while at GSK Biologicals, Dr. Slaoui engineered the development of a robust vaccines pipeline, including Rotarix to prevent infantile gastroenteritis, Synflorix to prevent Pneumococcal disease, and Cervarix to prevent cervical cancer. He also served as a professor of Immunology at the University of Mons, Belgium.
Dr. Slaoui has authored more than 100 scientific papers and presentations and is a member of the PhRMA Foundation Board of Directors, Advisory Board of Qatar Foundation, National Institutes of Health Advisory Committee to the Director, and the Biotechnology Industry Organization Board of Directors.
Moncef earned a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles, Belgium, and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston.